IL-1βattenuates IFN-αβ-induced antiviral activity and STAT1 activation in the liver: Involvement of proteasome-dependent pathway

Journal of Immunology

Volumn 165, Issue 7, 2000, Pages 3959-3965

  Tian, Z ^a   Shen, X ^a   Feng, H ^a   Gao, B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MUTANT PROTEIN; PROTEASOME; STAT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INFLAMMATION; KUPFFER CELL; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN; VIRUS HEPATITIS; WESTERN BLOTTING;

EID: 0034292338     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.7.3959     Document Type: Article

References (59)

1. Therapy of hepatitis C: Overview
2. Standards of treatment in chronic hepatitis C
3. Combination therapy with interferon α and Ribavirin as retreatment of interferon relapse in chronic hepatitis C
4. Phase II clinical trial of combined natural interferon-32 β plus recombinant interferon-γ treatment of chronic hepatitis B
5. The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C
6. Hepatitis C and alcohol
7. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers
8. Efficacy of interferon therapy in patients with chronic hepatitis C: Comparison between non-drinkers and drinkers
9. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C
10. Advances in the treatment of hepatitis C
11. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase
12. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway
13. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
14. Interferons activate p42/44 MAP kinase and JAK-STAT signaling pathways in hepatocytes: Differential regulation by acute ethanol via a PKC-dependent mechanism
15. Effectiveness of interferon-α therapy in chronic hepatitis C is associated with the amount of interferon-α receptor mRNA in the liver
16. Quantitative analysis of interferon αβ receptor mRNA in the liver of patients with chronic hepatitis C: Correlation with serum hepatitis C virus-RNA levels and response to treatment with interferon
17. Expression of interferon receptor genes (IFN-α-R1 and IFN-α-R2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection
18. Development of antibodies to interferon beta in patients: Technical and biological aspects
19. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB)
20. Cytokine gene expression in cirrhotic and non-cirrhotic human liver
21. Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial
22. Production of interleukin-1β and interleukin-6 in hepatoblastoma
23. Cytokines and the molecular mechanisms of alcoholic liver disease
24. Cytokines and alcoholic liver disease
25. Cytokines in alcoholic liver disease
26. Cytokines in alcoholic liver cirrhosis
27. Tumour necrosis factor, interleukin-1 and interleukin-6 in alcoholic cirrhosis
28. Interleukin-l
29. NF-κB: A lesson in family values
30. IκB kinase: Beginning, not the end
31. Regulation of NF-κB activation by MAP kinase cascades
32. How cells respond to interferons
33. Signaling pathways activated by interferons
34. Signal transduction in the interferon system
35. Interferon signal transduction
36. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease
37. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
38. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
39. Effects of short and long term ethanol on the activation of STAT3 in normal and regenerating liver
40. Transcription of the rat crib adrenergic receptor gene in liver is controlled by three promoters
41. cDNA structures and regulation of two interferon-induced human Mx proteins
42. Separation of Kupffer and endothelial cells of the rat liver by centrifugal elutriation
43. Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high-efficiency DNA transfer
44. Cross-talk between α(1B)-adrenergic receptor (α(IB)AR) and interleukin-6 (IL-6) signaling pathways. Activation of α(1b)AR inhibits il-6-activated STAT3 in hepatic cells by a p42/44 mitogen-activated protein kinase-dependent mechanism
45. The role of Kupffer cells in liver injury
46. Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1
47. Inactivation of Kupffer cells prevents early alcohol-induced liver injury
48. Structure of the gene for a carbohydrate-binding receptor unique to rat Kupffer cells
49. Brefeldin A arrests the intracellular transport of viral envelope proteins in primary cultured rat hepatocytes and HepG2 cells
50. IL- 1, EGF, and HGF suppress the antiviral activity of interferon in primary monkey hepatic parenchymal cells
51. Interleukin-I can inhibit interferon-β synthesis and its antiviral action: Comparison with tumor necrosis factor
52. Impaired antiviral response in human hepatoma cells
53. Regulation of interferon-γ-activated STAT1 by the ubiquitin-proteasome pathway
54. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-γ
55. Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1β on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells
56. Involvement of proteasomes in regulating JAK-STAT pathway upon interleukin-2 stimulation
57. Interleukin-3-induced activation of the JAK-STAT pathway is prolonged by proteasome inhibitors
58. Termination of growth hormone pulse-induced STAT5b signaling
59. Negative regulation of the JAK/STAT pathway